NEWS
LATEST
FULL LIST
-
The $150 Bioprinter Extruder That Anyone Can Build
Most conversations about biofabrication focus on what the technology might eventually produce, organs, tissue implants, patient-specific grafts. Fewer focus on the practical question of who can actually access the tools to do that work. A previous paper published in HardwareX and available open-access via PubMed Central addresses that question directly, by publishing the full design…
-
Cellbricks Therapeutics Raises €10M to Advance Biofabricated Tissue Implants for Wound Care and Reconstructive Surgery
A Berlin and Boston-based tissue engineering company has raised €10 million to move living, vascularized human tissue implants through preclinical validation and closer to patients. Cellbricks Therapeutics announced the financing on March 25, 2026, framing it as the capital needed to do the hard translational work the field has long demanded but rarely seen executed.…
-
NAMs, New Approach Methodologies for Drug Discovery: What It Means for the Future of Alternatives to Animal Testing and Biofabrication
A landmark review published in Cell by Stanford’s Joseph C. Wu and colleagues maps the rise of New Approach Methodologies, human-centric tools that are beginning to replace animal models in drug discovery, and what this shift means for organoids, bioprinting, and the broader biofabrication sector.
-
Canada Just Bet Another $280M on Bioprinted Medicines, Here’s What It Means for the Industry
The Government of Canada’s $280M bet on Aspect Biosystems signals that biofabrication is becoming a matter of national industrial strategy, with parallels to how ARPA-H is approaching regenerative medicine in the U.S.
-
UC San Diego’s ARPA-H Project Targets the A Different Approach for the Bioprinted LIVER Program
The Advanced Research Projects Agency for Health (ARPA-H) has recently funded several large initiatives under its Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program aimed at advancing implantable bioengineered organs. Among them is a $25.8 million project led by Shaochen Chen at University of California San Diego that seeks to develop a patient-specific, 3D bioprinted human…
-
Japan Moves Toward First Commercial iPS Cell Therapies
Japan is poised to reach a historic milestone in regenerative medicine. A panel of experts advising the country’s Ministry of Health, Labour and Welfare has conditionally endorsed two therapies derived from induced pluripotent stem (iPS) cells, potentially paving the way for the world’s first approved commercial products based on the technology. The recommendation, issued in…
-
Cellares Raises $257M to Industrialize Cell Therapy Manufacturing
Cellares has secured $257 million in Series D financing to accelerate the industrialization of cell therapy manufacturing, positioning itself as one of the most heavily funded automation platforms in advanced biomanufacturing. The round was co-led by BlackRock and Eclipse Ventures, with participation from T. Rowe Price, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates…
-
UT Southwestern VITAL Program Wins ARPA-H Award to Bioprint Personalized, Immune-Compatible Livers
UT Southwestern Medical Center has been awarded up to $25 million from Advanced Research Projects Agency for Health (ARPA-H) to develop fully personalized, bioprinted human livers using patients’ own cells. The initiative, known as Vascularized Immunocompetent Tissue as an Alternative Liver (VITAL), is part of ARPA-H’s PRINT program and aims to address the persistent shortage…
-
United Therapeutics Reports Breakthrough Phase 1 Results for Bioengineered Liver Support System
United Therapeutics has announced positive Phase 1 clinical results for miroliverELAP®, marking the world’s first FDA-cleared human trial of a bioengineered liver support system. Developed by its subsidiary Miromatrix Medical, the platform represents a major milestone in regenerative medicine and organ manufacturing. The results suggest that engineered liver constructs may soon offer lifesaving temporary support…
-
Aspect Biosystems and Novo Nordisk Deepen Partnership to Advance Curative Diabetes Therapies
In a major step forward for regenerative medicine and diabetes care, Aspect Biosystems and Novo Nordisk have announced a new phase of their strategic partnership focused on developing potentially curative cell-based therapies for diabetes. The expanded collaboration builds on a relationship launched in 2023 and reflects growing momentum in the effort to replace, repair, or…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 